Abstract: Magnesium is formulated in combination with vitamin E, vitamin C, folate, selenium, and optionally melatonin a unit dosage form for oral administration, for the treatment of vasoconstriction and the physiological and pathological conditions giving rise to vasoconstriction. These active agents complement each other in suppressing these conditions, using a variety of mechanisms operating in conjunction with one another. The inclusion of magnesium in a plurality of forms provides additional advantages in terms of controlling and sustaining the release of magnesium in locations along the digestive tract where the magnesium will have its greatest effectiveness as a therapeutic agent, thus improving control over the clinical bioavailability of magnesium and in improving the selection of appropriate therapeutic ranges.
Abstract: A method is described for treating bacterially induced meningitis, comprising administering a prostane derivative of formula I or Ia ##STR1## wherein X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as described below, and the --O--R.sup.3 -- group is in the .alpha.- or .beta.-configuration. The prostane derivative can optionally comprise or serve as an adjuvant, and it can be administered in combination with an antiobiotic.
Type:
Grant
Filed:
April 23, 1998
Date of Patent:
March 21, 2000
Assignee:
Schering Aktiengesellschaft
Inventors:
Peter Scholz, Jorg Weber, Klemens Angstwurm
Abstract: Nicotine-responsive neuropsychiatric disorders can be treated by administering a nicotine antagonist, particularly mecamylamine. Combination therapy of mecamylamine with a neuroleptic drug also is disclosed. The neuropsychiatric disorders include Tourette's syndrome, schizophrenia, depression, bipolar disorder, tremors, attention deficit hyperactivity disorder, obsessive-compulsive disorder, hemidystonia, rage outbursts and tardive dyskinesia.
Type:
Grant
Filed:
November 23, 1998
Date of Patent:
March 7, 2000
Assignee:
University of South Florida
Inventors:
Paul R. Sanberg, Roland D. Shytle, Archie A. Silver
Abstract: Use of bambuterol or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical preparation with lipid lowering effect.
Type:
Grant
Filed:
November 17, 1998
Date of Patent:
March 7, 2000
Assignee:
Astra Aktiebolag
Inventors:
Carl-Axel Wilhelm Edvard Bauer, Leif .ANG.ke Svensson
Abstract: The present invention provides a pharmaceutical composition comprising 5,6-dihydrodibenzo[a,g]quinolizinium derivative and the salts thereof of formula (I) which specifically inhibits the sterol 14-reductase which is involved in the distal pathway of cholesterol biosynthesis, and the use of the compound of formula (I) for treating hypercholesterolaemia or hyperlipidaemia.
Type:
Grant
Filed:
January 22, 1999
Date of Patent:
February 29, 2000
Assignee:
Hanwha Corporation
Inventors:
Jung Ho Kim, Tae Neung Jhong, Young Ki Paik, Joon Seo Park, Eui Deok Kim, You Suk Lee, Seung Un Kim
Abstract: The present invention provides orally administrable pharmaceutical compositions containing an inhibitor of gastrointestinal lipase, and at least one compound selected from the group consisting of chitosan, its derivatives and salts thereof. Methods are provided for preventing and treating anal leakage of oil in a patient to whom a composition containing an inhibitor of gastrointestinal lipase is orally administered.
Type:
Grant
Filed:
August 10, 1999
Date of Patent:
February 29, 2000
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Jacques Bailly, Andre Fleury, Paul Hadvary, Hans Lengsfeld, Hans Steffen
Abstract: A method of producing local anesthesia in a mammal experiencing pain in an epithelial tissue region is described. The method includes topically administering to the region, in a suitable pharmaceutical vehicle, an effective dose of a long-acting sodium channel blocking compound.
Type:
Grant
Filed:
April 2, 1998
Date of Patent:
February 29, 2000
Assignee:
The Regents of the University of California
Abstract: The use of agonists of the peroxisome proliferator activated receptor alpha (PPAR.alpha.) for the manufacture of a medicament for the treatment of obesity and methods of treating obesity comprising the administration of a therapeutic amount of a PPAR.alpha. agonist.
Abstract: An oil/fat composition is provided which lowers the blood cholesterol level of a person having a high cholesterol level when used in daily life similarly to ordinary fats and is usable without posing any problem concerning appearance, flavor, heat cooking, etc. as compared with generally edible fats, wherein the oil/fat composition contains a phytosterol contained in an oil/fat containing one or more polyhydric alcohol/fatty acid esters each having a degree of esterification of 2 or higher and containing at least one hydroxyl group remaining unesterified.
Abstract: The present invention relates, in general, to a method of preventing or delaying the onset of Alzheimer's disease and related neurodegenerative disorders. The invention also relates to a method of treating Alzheimer's disease and related neurodegenerative disorders so as to ameliorate the further progress of symptoms. The methods involve the administration of a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor blocking agent. According to indication, the present method can be applied to individuals who are currently asymptomatic but at risk of developing Alzheimer's disease, to individuals who have mild cognitive symptoms that may either denote an incipient prodrome of Alzheimer's disease or represent early symptoms (prodromal stage), or to individuals who have a clinical diagnosis of Alzheimer's disease.
Type:
Grant
Filed:
April 14, 1997
Date of Patent:
February 15, 2000
Assignee:
Duke University
Inventors:
John C. S. Breitner, Kathleen A. Welsh-Bohmer
Abstract: The invention suggests a novel medical use of pure bilobalide or Ginkgo biloba extract with an increased bilobalide content as an anxiolytic or antidepressant.
Abstract: Blood cholesterol and/or blood triglycerides are reduced in a mammalian subject by administering an effective amount of tert-butylhydroquinone or a salt thereof. The mammalian subject is preferably human. Additionally, a preparation of tert-butylhydroquinone in dosage unit form is provided to reduce blood cholesterol and/or blood triglycerides. The preparation is advantageously designed for oral administration.
Type:
Grant
Filed:
January 11, 1999
Date of Patent:
February 1, 2000
Assignee:
Eastman Chemicals Company
Inventors:
William Lawrence Stone, Andreas Micheal Papas
Abstract: A low molecular weight fraction of gugulipid as antisebum and/or antioxidant active in cosmetic skin care compositions and methods. The low molecular weight fraction is capable of delivering dual benefit to the skin: controlling or preventing sebum secretion (oily skin conditions) and protecting the skin from free radical damage.
Type:
Grant
Filed:
November 13, 1997
Date of Patent:
February 1, 2000
Assignee:
Elizabeth Arden Co., Division of Conopco, Inc.
Abstract: Compounds represented by the following general formula: ##STR1## wherein Rf and Rf' mean a perfluoroalkyl group having 1-20 carbon atoms or a (.omega.-H-perfluoroalkyl group represented by the formula H(CF.sub.2).sub.t in which t stands for an integer of 1-20, R.sup.2 denotes a hydrogen atom, a straight-chain or branched aliphatic hydrocarbon group having 1-20 carbon atoms, an alicyclic or aromatic hydrocarbon group having 5-10 carbon atoms, a perfluoroalkyl group having 1-20 carbon atoms, or .omega.-H-perfluoroalkyl group represented by the formula H(CF.sub.2).sub.u - in which u stands for an integer of 1-20, X and Y mean individually a single bond, --CO-- or a divalent hydrocarbon group having 1-6 carbon atoms, l stands for a number of 2-16, and m and n are individually a number of 1-6. The compounds are useful for preparing fluorine-modified silicone derivatives suitable for cosmetic compositions.
Abstract: The present invention relates certain mercaptoacetylamide disulfide derivatives of the formula ##STR1## useful in treating patients suffering from hypertriglyceridemia, atherosclerosis and hypercholestrolemia.
Type:
Grant
Filed:
November 24, 1997
Date of Patent:
January 11, 2000
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Gary A. Flynn, John F. French, Richard C. Dage
Abstract: This invention relates to a method for enhancing the absorption of oil soluble (lipophilic) compounds such as oil soluble vitamins, hormones, nutrients and drugs in an animal. The inventive method comprises administering a lipophilic compound in conjunction with a structured glyceride component characterized in that at least 40% of the glyceride species have: (i) about 33 to 70 wt. % of acyl moieties having 4 to 12 carbon atoms; (ii) about 30 to 67 wt. % of acyl moieties having more than 12 carbon atoms; and (iii) an equivalent carbon number greater than 30 and less than 48. This invention also relates to compositions suitable for administrating to an animal comprising a lipophilic compound and a structured glyceride component characterized in that at least 40% of the glyceride species have: (i) about 33 to 70 wt. % of acyl moieties having 4 to 12 carbon atoms; (ii) about 30 to 67 wt. % of acyl moieties having more than 12 carbon atoms; and (iii) an equivalent carbon number greater than 30 and less than 48.
Type:
Grant
Filed:
December 16, 1997
Date of Patent:
January 11, 2000
Assignee:
Abbott Laboratories
Inventors:
Stephen J. DeMichele, Theresa W. Lee, Patrick Tso
Abstract: Combinations of a glitazone antidiabetic agent and a biguanide antidiabetic agent, and optionally a sulfonylurea antidiabetic agent, are useful for treating diabetes mellitus and improving glycemic control.
Abstract: The invention provides methods of using photoactivated hypericin compounds which, when photoactivated using visible or UV-A light, are useful for treating numerous diseases and disorders in mammals. The compounds of the invention are useful for inhibiting the proliferation and accumulation of mammalian leukocytes and for inducing apoptosis in mammalian leukocytes.
Type:
Grant
Filed:
July 3, 1997
Date of Patent:
December 14, 1999
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Floyd Eliot Fox, Alain H. Rook, Alfonso J. Tobia
Abstract: Disclosed are methods for the application of a cyanoacrylate/anti-microbial composition over mammalian skin surfaces to peri-wound and peri-mucosal areas. The composition can also be applied over medicament that has been applied onto the skin surface.
Type:
Grant
Filed:
November 3, 1997
Date of Patent:
December 14, 1999
Assignee:
MedLogic Global Corporation
Inventors:
Ian N. Askill, Michael M. Byram, Richard J. Greff
Abstract: Compositions and methods for the modulation of melanin production are provided in which the active component is an adenosine receptor antagonist or agonist.